NU-9 Is Now AKV9, and Doing Well in Preclinical Studies
Jun 10, 2022 · AKAVA Therapeutics’ experimental therapy AKV9, formerly NU-9, was superior to approved therapies for amyotrophic lateral sclerosis (ALS) at improving the health of lab-grown upper motor neurons from a mouse model of the disease, a study shows.
Experimental drug NU-9 shows promise for Alzheimer's and ALS …
13 hours ago · NU-9 reduced the amount of protein buildup within the cell and along the cell's branches, or dendrites. Even after the researchers removed NU-9 from the treated cells, the drug still had a lasting ...
ALS drug effectively treats Alzheimer’s disease in new animal study
1 day ago · NU-9 reduced the amount of protein buildup within the cell and along the cell’s branches, or dendrites. Even after the researchers removed NU-9 from the treated cells, the drug still had a lasting, protective effect. After demonstrating NU-9’s success in cell cultures, the team tested its effectiveness in a whole animal model. They ...
NU-9 Update: Experimental drug repairs upper motor neurons in …
May 19, 2022 · Early research on NU-9, an experimental drug invented and developed by members of the Les Turner ALS Center at Northwestern Medicine, has shown the ability to lengthen the axons of diseased upper motor neurons in an SOD1 ALS mouse model.
Potential ALS treatment may repair axons of diseased neurons
May 18, 2022 · New research on the experimental drug, NU-9, invented and developed by two Northwestern University scientists to treat ALS (amyotrophic lateral sclerosis), shows it is more effective than existing FDA-approved drugs for the disease.
Research grant provides $7.3M for NU-9 development
Nov 14, 2024 · Researchers at Northwestern University received a $7.3 million research grant from the National Institute on Aging to expand their work on NU-9, which has shown promise in amyotrophic lateral sclerosis (ALS) preclinical studies, and explore its effectiveness in other neurodegenerative diseases.
Reasons for Hope in ALS Research with the Discovery of NU-9
In a study funded in part by The ALS Association’s TREAT ALS program, researchers from Northwestern University have identified the first compound (NU-9) that eliminates the ongoing degeneration of diseased upper motor neurons, a key contributor to ALS.
National Institute on Aging invests an additional $7.3 million into NU-9
Nov 6, 2024 · With its ability to improve neuron health, experimental drug NU-9 has already shown promise in reversing amyotrophic lateral sclerosis (ALS). Now, the National Institute on Aging (NIA) has provided approximately $7.3 million to fund exploration into the Northwestern University-invented drug’s effectiveness in other neurodegenerative diseases.
NU-9 improves health of hSOD1G93A mouse upper motor …
Mar 30, 2022 · We report that NU-9, the first compound reported to improve neuronal integrity of UMNs that are diseased due to mSOD1 toxicity and TDP-43 pathology in vivo 38 was more effective than...
Update on promising drug NU-9 - HSP Research Foundation
Sep 2, 2022 · CHICAGO — New research on the experimental drug, NU-9 to treat MND (motor neuron disease) otherwise known as ALS (amyotrophic lateral sclerosis), shows it is more effective than existing FDA-approved drugs for the disease. More importantly, NU-9 has an enhanced effect when given in combination with those drugs, riluzole and edaravone.